---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Dosage forms and strengths"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Dosage forms and strengths. Topics: Dosage form in phase 3: solution for intravitreal injection, Molecule and dose volume in ARCHER II: 5 mg in 25 microliters, Expression system and glycosylation, and Doses and injection volumes in the phase 1 glaucoma studies. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Dosage form in phase 3: solution for intravitreal injection

> “Form: solution for injection; Route of Administration: IVT injection”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-2.1.2.2-2"></a>

### Molecule and dose volume in ARCHER II: 5 mg in 25 microliters

> “Small 50 kD Fab antibody”
> “Non-pegylated, with low viscosity and high potency (<10 pM)”
> “5 mg administered in 25 microliter dose (in ongoing Phase 3 ARCHER II trial)”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.2-3"></a>

### Expression system and glycosylation

> “produced in Chinese hamster ovary (CHO) cells, non-glycosylated”

Source: [WHO proposed INN List 134 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl134.pdf)

<a id="topic-2.1.2.2-4"></a>

### Doses and injection volumes in the phase 1 glaucoma studies

> “Doses were administered at volumes of 20 μL (1 mg dose), 50 μL (2.5 mg dose), and 100 μL (5 mg dose), respectively.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.2-5"></a>

### Concentration, commercial presentation, packaging, and storage

No evidence found.

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
